NCT05955261 2026-04-13
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Suspended
Clinical Trials
16 trialsNCT00801489 2026-03-30
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05558124 2026-02-27
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT03672539 2026-02-20
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04915612 2026-02-20
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03737955 2026-01-28
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
University of Washington
Phase 2 Recruiting
NCT03568994 2026-01-27
ATACC AML
Baylor College of Medicine
Phase EARLY_PHASE1 Completed
NCT05183035 2026-01-13
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
PedAL BCU, LLC
Phase 3 Recruiting
NCT01409161 2025-12-17
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06448013 2025-12-15
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03589729 2025-11-20
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03900949 2025-10-28
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04385290 2025-09-08
MOSAIC
Technische Universität Dresden
Phase 1/2 Recruiting
NCT05716009 2025-05-06
GO-TAG
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04070768 2025-05-04
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Big Ten Cancer Research Consortium
Phase 1 Completed
NCT04050280 2025-05-01
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
University of Maryland, Baltimore
Phase 2 Recruiting